Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi
- PMID: 9596106
Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi
Abstract
The aim of this study was to systematically compare the interaction of the long-acting beta2-adrenoceptor agonists formoterol and salmeterol with short-acting beta2-adrenoceptor agonists in contracted human bronchi. Human bronchi were obtained at thoracotomy from patients with lung cancer. Formoterol or salmeterol at concentrations inducing up to 92 and 94% of their maximal relaxant effect, respectively, were added to bronchial rings contracted with carbachol (10(-6) M). After a time period of 30 min, concentration-response curves for the short-acting beta2-adrenoceptor agonists, salbutamol, terbutaline, isoprenaline and fenoterol were recorded. Administration of equieffective concentrations of salmeterol and formoterol, resulted in only salmeterol inducing a shift to the right of isoprenaline, terbutaline, fenoterol and salbutamol concentration-response curves. The rank order of shift was salbutamol > fenoterol > terbutaline > isoprenaline. Formoterol, up to concentrations of 3x10(-9) M induced submaximal relaxation resulting in no shift in short-acting beta2-adrenoceptor agonist concentration-response curves. Salmeterol but not formoterol appears to antagonize the relaxation of human contracted bronchi induced by short-acting beta2-agonists. These results obtained in vitro cannot be translated in clinical terms. This study, however, highlights the need for clinical studies on the interaction of long-acting and short-acting beta2-adrenoceptor agonists in acute severe asthma.
Similar articles
-
Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus.Eur Respir J. 1994 May;7(5):914-20. Eur Respir J. 1994. PMID: 7914176
-
Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.Eur Respir J. 2007 Mar;29(3):575-81. doi: 10.1183/09031936.00032806. Epub 2006 Nov 29. Eur Respir J. 2007. PMID: 17135231
-
Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.Br J Pharmacol. 2004 Jan;141(1):163-71. doi: 10.1038/sj.bjp.0705599. Epub 2003 Dec 8. Br J Pharmacol. 2004. PMID: 14662724 Free PMC article.
-
Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.Lung. 1996;174(1):1-22. doi: 10.1007/BF00167947. Lung. 1996. PMID: 8746998 Review.
-
Pharmacological similarities and differences between beta2-agonists.Respir Med. 2001 Aug;95 Suppl B:S7-11. doi: 10.1053/rmed.2001.1139. Respir Med. 2001. PMID: 11534896 Review.
Cited by
-
Benefit-risk assessment of long-acting beta2-agonists in asthma.Drug Saf. 2004;27(4):243-70. doi: 10.2165/00002018-200427040-00003. Drug Saf. 2004. PMID: 15003036 Review.
-
Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms.Clin Rev Allergy Immunol. 2006 Oct-Dec;31(2-3):119-30. doi: 10.1385/CRIAI:31:2:119. Clin Rev Allergy Immunol. 2006. PMID: 17085788 Review.
-
Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):147-157. doi: 10.1002/psp4.12270. Epub 2017 Dec 27. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 29280349 Free PMC article.
-
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.Thorax. 2001 Jul;56(7):529-35. doi: 10.1136/thorax.56.7.529. Thorax. 2001. PMID: 11413351 Free PMC article. Clinical Trial.
-
Limited beta2-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics.Respir Res. 2006 Jan 31;7(1):19. doi: 10.1186/1465-9921-7-19. Respir Res. 2006. PMID: 16448568 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources